GlassScriptPhysician profile
Andres Morales
NPI 1245276500
$7,841.31
in general payments reported to CMS, 2019-2025
45 companies · $3,161 in 2025
The $3,161 reported for 2025 was more than what 80% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $110 · 2021: $541 · 2022: $833 · 2023: $1,449 · 2024: $1,488 · 2025: $3,161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,025 · Travel and Lodging: $1,016 · Education: $57.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,024.87 |
| Travel and Lodging | $1,016.49 |
| Education | $57.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,634.86 | 2021-2025 | |
| Livanova USA, INC. | $1,581.13 | 2021-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Ucb, INC. | $382.84 | 2021-2025 | Rystiggo, Briviact, Fintepla |
| Pfizer INC. | $315.65 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $256.45 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $243.03 | 2019-2025 | Ingrezza |
| Sk Life Science, INC. | $222.29 | 2020-2025 | |
| Axsome Therapeutics, INC. | $204.42 | 2025 | Symbravo |
| Lundbeck LLC | $198.62 | 2022-2025 | Vyepti, Rexulti |
| Lilly USA, LLC | $185.58 | 2022-2025 | Amyvid, Kisunla |
| Sumitomo Pharma America, INC. | $145.61 | 2023-2024 | Aptiom |
| Astrazeneca Pharmaceuticals LP | $114.58 | 2021-2024 | Lynparza |
| Genzyme Corporation | $91.02 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $88.27 | 2023 | Austedo, Austedo Xr |
| Alexion Pharmaceuticals, INC. | $84.64 | 2019-2024 | Ultomiris |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andres Morales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.